Payment overview · 2025
General Payments
$725.11
42 reported records · 12 companies
Healthcare provider profile · identity verified
Karthikeya Devireddy, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LOS BANOS, CA · NPI 1780615542
Verified facts
What the public records show
CMS Open Payments records show Karthikeya Devireddy, MD received $725.11 in general payments during 2025 across 42 reported records.
Lilly USA, LLC accounted for 41.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Kerendia, Mounjaro, Ozempic, Paxlovid, Rybelsus, Xifaxan.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Kerendia by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 355 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 232 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $303.98 | 41.9% | 21 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $89.46 | 12.3% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $56.84 | 7.8% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $51.19 | 7.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $49.29 | 6.8% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $34.02 | 4.7% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $31.94 | 4.4% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $30.43 | 4.2% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.73 | 3.1% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $20.34 | 2.8% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.48 | 2.4% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $17.41 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $725.11 | 42 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $270.72 | 16 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $89.46 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $56.84 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $56.84 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $51.19 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $49.29 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $34.02 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $31.94 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $30.43 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $30.43 | 2 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $30.43 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $25.83 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $23.46 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $23.10 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $22.80 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $22.73 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $20.34 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.48 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $17.41 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $15.81 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $14.62 | 1 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $14.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 355 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 106 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 13 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
103 | 22 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
37 | 13 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
355 | 84 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
88 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
106 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
232 | 38 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1093 | 347 |
| Lisinopril | Lisinopril | 609 | 194 |
| Amlodipine Besylate | Amlodipine Besylate | 608 | 175 |
| Metformin Hcl | Metformin Hcl | 573 | 177 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 529 | 85 |
| Levothyroxine Sodium | Levothyroxine Sodium | 519 | 153 |
| Losartan Potassium | Losartan Potassium | 421 | 167 |
| Furosemide | Furosemide | 401 | 74 |
| Gabapentin | Gabapentin | 392 | 111 |
| Omeprazole | Omeprazole | 383 | 129 |
| Jardiance | Empagliflozin | 355 | 84 |
| Pantoprazole Sodium | Pantoprazole Sodium | 295 | 67 |
| Metoprolol Tartrate | Metoprolol Tartrate | 276 | 69 |
| Trazodone Hcl | Trazodone Hcl | 242 | 57 |
| Eliquis | Apixaban | 232 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 207 | 62 |
| Sertraline Hcl | Sertraline Hcl | 205 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 200 | 76 |
| Simvastatin | Simvastatin | 169 | 60 |
| Carvedilol | Carvedilol | 167 | 53 |
| Clopidogrel | Clopidogrel Bisulfate | 163 | 53 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 159 | 65 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 150 | 62 |
| Lorazepam | Lorazepam | 140 | 36 |
| Famotidine | Famotidine | 139 | 42 |
| Glipizide | Glipizide | 137 | 69 |
| Atenolol | Atenolol | 126 | 28 |
| Baclofen | Baclofen | 123 | 32 |
| Alendronate Sodium | Alendronate Sodium | 119 | 40 |
| Potassium Chloride | Potassium Chloride | 119 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 118 | 38 |
| Zolpidem Tartrate | Zolpidem Tartrate | 112 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 110 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 109 | 53 |
| Quetiapine Fumarate | Quetiapine Fumarate | 107 | 18 |
| Donepezil Hcl | Donepezil Hcl | 106 | 19 |
| Ozempic | Semaglutide | 106 | 22 |
| Mirtazapine | Mirtazapine | 104 | 20 |
| Montelukast Sodium | Montelukast Sodium | 104 | 39 |
| Myrbetriq | Mirabegron | 103 | 22 |
| Oxycodone Hcl | Oxycodone Hcl | 101 | 16 |
| Tramadol Hcl | Tramadol Hcl | 97 | 23 |
| Doxycycline Hyclate | Doxycycline Hyclate | 90 | 59 |
| Pravastatin Sodium | Pravastatin Sodium | 88 | 32 |
| Trulicity | Dulaglutide | 88 | 14 |
| Memantine Hcl | Memantine Hcl | 87 | 13 |
| Azithromycin | Azithromycin | 86 | 60 |
| Ibuprofen | Ibuprofen | 86 | 35 |
| Spironolactone | Spironolactone | 84 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 82 | 27 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 82 | 23 |
| Allopurinol | Allopurinol | 81 | 23 |
| Levetiracetam | Levetiracetam | 78 | 15 |
| Divalproex Sodium | Divalproex Sodium | 75 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 73 | 17 |
| Ondansetron Odt | Ondansetron | 70 | 29 |
| Diclofenac Sodium | Diclofenac Sodium | 68 | 25 |
| Pioglitazone Hcl | Pioglitazone Hcl | 68 | 18 |
| Buspirone Hcl | Buspirone Hcl | 67 | 18 |
| Glimepiride | Glimepiride | 67 | 23 |
| Lactulose | Lactulose | 67 | 27 |
| Meloxicam | Meloxicam | 67 | 20 |
| Warfarin Sodium | Warfarin Sodium | 67 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 66 | 14 |
| Latanoprost | Latanoprost | 66 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 65 | 13 |
| Risperidone | Risperidone | 65 | suppressed |
| Ezetimibe | Ezetimibe | 63 | 11 |
| Xarelto | Rivaroxaban | 62 | 12 |
| Alprazolam | Alprazolam | 61 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 61 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 59 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 58 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 58 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 58 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 57 | 19 |
| Bupropion Xl | Bupropion Hcl | 56 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 56 | 29 |
| Paroxetine Hcl | Paroxetine Hcl | 55 | 21 |
| Lidocaine | Lidocaine | 53 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 53 | 27 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 51 | 20 |
| Benztropine Mesylate | Benztropine Mesylate | 49 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 49 | 11 |
| Januvia | Sitagliptin Phosphate | 48 | 16 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 48 | 32 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 47 | 12 |
| Naproxen | Naproxen | 46 | 12 |
| Lovastatin | Lovastatin | 43 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 42 | 14 |
| Clonazepam | Clonazepam | 41 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 41 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 40 | 13 |
| Farxiga | Dapagliflozin Propanediol | 37 | 13 |
| Midodrine Hcl | Midodrine Hcl | 37 | suppressed |
| Nystatin | Nystatin | 36 | 23 |
| Cephalexin | Cephalexin | 35 | 14 |
| Insulin Lispro | Insulin Lispro | 34 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 34 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 34 | 14 |
| Nitroglycerin | Nitroglycerin | 34 | 11 |
| Folic Acid | Folic Acid | 33 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 33 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 31 | suppressed |
| Haloperidol | Haloperidol | 31 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 29 | suppressed |
| Brilinta | Ticagrelor | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 26 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 26 | suppressed |
| Levofloxacin | Levofloxacin | 26 | 18 |
| Ondansetron Hcl | Ondansetron Hcl | 26 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 25 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 25 | suppressed |
| Prednisone | Prednisone | 25 | 16 |
| Finasteride | Finasteride | 24 | suppressed |
| Klor-Con 10 | Potassium Chloride | 24 | suppressed |
| Gemtesa | Vibegron | 23 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Methadone Hcl | Methadone Hcl | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 14 |
| Mupirocin | Mupirocin | 21 | 14 |
| Topiramate | Topiramate | 21 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 20 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 16 |
| Diazepam | Diazepam | 19 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 19 | suppressed |
| Telmisartan | Telmisartan | 19 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 18 | suppressed |
| Rybelsus | Semaglutide | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 12 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 18 | suppressed |
| Xifaxan | Rifaximin | 18 | suppressed |
| Amantadine | Amantadine Hcl | 17 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Celecoxib | Celecoxib | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Carisoprodol | Carisoprodol | 16 | suppressed |
| Constulose | Lactulose | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | suppressed |
| Kerendia | Finerenone | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Lacosamide | Lacosamide | 16 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Nyamyc | Nystatin | 14 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Cefdinir | Cefdinir | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Pilocarpine Hcl | Pilocarpine Hcl | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Levemir | Insulin Detemir | 12 | suppressed |
| Novolin R | Insulin Regular, Human | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Indomethacin | Indomethacin | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $725.11 · 42 records | Lilly USA, LLC | AIRSUPRA, CAPVAXIVE, Dexcom G6 Transmitter, ENFLONSIA, FREESTYLE LIBRE 3, GARDASIL 9, JARDIANCE, Kerendia, M-M-R II, MOUNJARO, NURTEC ODT, Ozempic, PAXLOVID, REPATHA, ROTATEQ, Rybelsus, The Cologuard Plus Collection Kit, VAXNEUVANCE, Veozah, XIFAXAN, ZAVZPRET, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error